M C Etienne

Medicine · Health Sciences

30h-index3.7kcitations81works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Colorectal Cancer Treatments and Studies(31), Cancer Treatment and Pharmacology(18), Pancreatic and Hepatic Oncology Research(15), Gastric Cancer Management and Outcomes(9), Cancer therapeutics and mechanisms(8)

Publications81 total

From Marie Curie to Modern Equity: Advancing Gender Diversity in Radiation Oncology
International Journal of Radiation Oncology*Biology*Physics·2025
Hyperhomocysteinemia and high doses of nilotinib favor cardiovascular events in chronic phase Chronic Myelogenous Leukemia patients
Haematologica·2015· 12 citedOpen Access
Anomalies unguéales révélant une amylose systémique AL
La Revue de Médecine Interne·2014· 6 cited
Achieving deeper molecular response is associated with a better clinical outcome in chronic myeloid leukemia patients on imatinib front-line therapy
Haematologica·2013· 60 citedOpen Access
Fit for Duty: Autonomic Nervous System Dysfunction in US Service Members (P05.201)
Neurology·2012
Prise en charge des mycoses urinaires
2007· 3 cited
ORL10 L’otite maligne externe en 2006
Journal de Radiologie·2006
Quel est votre diagnostic ?
Journal de Radiologie·2006· 2 cited
Thymidylate synthase (TS) and methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms: Relationships with capecitabine (X) pharmacodynamics in advanced breast cancer (ABC) patients (pts)
Journal of Clinical Oncology·2004
Analysis of the dinucleotide repeat polymorphism in the epidermal growth factor receptor (EGFR) in tumor and normal tissue of head and neck cancer (HNC) patients
Journal of Clinical Oncology·2004
Thymidylate synthase (TS) and methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms: Relationships with capecitabine (X) pharmacodynamics in advanced breast cancer (ABC) patients (pts)
Journal of Clinical Oncology·2004
Multicenter Phase II Feasibility Trial of High-Dose Tamoxifen in Patients With Refractory or Relapsed Multiple Myeloma
JNCI Journal of the National Cancer Institute·2004· 11 citedOpen Access
Dihydropyrimidine dehydrogenase circadian rhythm in mouse liver
European Journal of Cancer·2003· 37 cited
Pharmacokinetics of low-dose carboplatin and applicability of a method of calculation for estimating individual drug clearance
Annals of Oncology·2003· 12 citedOpen Access
Impact of the oxaliplatin-5 fluorouracil-folinic acid combination on respective intracellular determinants of drug activity
British Journal of Cancer·2002· 3 citedOpen Access
Impact of the oxaliplatin-5 fluorouracil-folinic acid combination on respective intracellular determinants of drug activity
British Journal of Cancer·2002· 56 citedOpen Access
Impact of thymidine phosphorylase surexpression on fluoropyrimidine activity and on tumour angiogenesis
British Journal of Cancer·2001· 29 citedOpen Access
Ternary combination of irinotecan, fluorouracil-folinic acid and oxaliplatin: results on human colon cancer cell lines
British Journal of Cancer·2001· 47 citedOpen Access
A multivariate analysis for predicting cisplatin-induced delayed emesis.
Oncology Reports·2000· 7 cited
An analysis of potential factors allowing an individual prediction of cisplatin-induced anaemia
European Journal of Cancer·2000· 38 cited
page 1 of 5Next →

Frequent Co-authors

G. Milano(46), N. Renée(18), Patricia Formento(18), Jean–Louis Fischel(13), M. Schneider(12), F Démard(11), M Francoual(8), Antoine Thyss(7), O. Dassonville(6), S. Chéradame(6), Marc Frénay(6), J. L. Formento(6), M. Namer(6), A. Thyss(5), Éric François(5), M Chazal(4), Xavier Pivot(4), J-L Fischel(4), Thierry Guillot(4), Ronald A. Fleming(3)